Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease
1
조회
0
다운로드
10
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to investigate the effect of hepatocellular carcinoma (HCC) surveillance using the Korea National Liver Cancer Screening Program on the receipt of curative treatment for HCC and mortality in patients with chronic liver disease. Methods: This population-based cohort study from the Korean National Health Insurance Service included 2003 to 2015 claims data collected from 1,209,825 patients aged ≥40 years with chronic hepatitis B, chronic hepatitis C, and liver cirrhosis. Patients were divided according to HCC surveillance using ultrasonography and serum alpha-fetoprotein every 6–12 months. The study outcomes were the receipt of curative treatment (surgical resection, radiofrequency ablation, or liver transplantation) and all-cause mortality. Results: The study population consisted of 1,209,825 patients with chronic hepatitis B, chronic hepatitis C, and liver cirrhosis (median age, 52.0 years; interquartile range, 46–55 years; 683,902 men [56.5%]). The proportion of participants who underwent HCC surveillance was 52.7% (n=657,889). During 10,522,940 person-years of follow-up, 74,433 HCC cases developed, including 36,006 patients who underwent curative treatment. The surveillance group had a significantly higher proportion of curative treatment for HCC than the non-surveillance group after adjusting for confounding factors (adjusted hazard ratio [HR], 5.64; 95% confidence interval [CI], 5.48–5.81). The surveillance group had a significantly lower mortality rate than the non-surveillance group (adjusted HR, 0.56; 95% CI, 0.55–0.56). Conclusions: HCC surveillance using the national screening program in patients with chronic viral hepatitis or liver cirrhosis provides better opportunity for curative treatment for HCC and improves overall survival.
Abstract
Background/Aims: This study aimed to investigate the effect of hepatocellular carcinoma (HCC) surveillance using the Korea National Liver Cancer Screening Program on the receipt of curative treatment for HCC and mortality in patients with chronic liver disease. Methods: This population-based cohort study from the Korean National Health Insurance Service included 2003 to 2015 claims data collected from 1,209,825 patients aged ≥40 years with chronic hepatitis B, chronic hepatitis C, and liver cirrhosis. Patients were divided according to HCC surveillance using ultrasonography and serum alpha-fetoprotein every 6–12 months. The study outcomes were the receipt of curative treatment (surgical resection, radiofrequency ablation, or liver transplantation) and all-cause mortality. Results: The study population consisted of 1,209,825 patients with chronic hepatitis B, chronic hepatitis C, and liver cirrhosis (median age, 52.0 years; interquartile range, 46–55 years; 683,902 men [56.5%]). The proportion of participants who underwent HCC surveillance was 52.7% (n=657,889). During 10,522,940 person-years of follow-up, 74,433 HCC cases developed, including 36,006 patients who underwent curative treatment. The surveillance group had a significantly higher proportion of curative treatment for HCC than the non-surveillance group after adjusting for confounding factors (adjusted hazard ratio [HR], 5.64; 95% confidence interval [CI], 5.48–5.81). The surveillance group had a significantly lower mortality rate than the non-surveillance group (adjusted HR, 0.56; 95% CI, 0.55–0.56). Conclusions: HCC surveillance using the national screening program in patients with chronic viral hepatitis or liver cirrhosis provides better opportunity for curative treatment for HCC and improves overall survival.
참고문헌 (28)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
- Zhang BH, "Randomized controlled trial of screening for hepatocellular carcinoma", J Cancer Res Clin Oncol, 130, pp.417~422 (2004)
- Chen JG, "Screening for liver cancer : results of a randomised controlled trial in Qidong, China", J Med Screen, 10, pp.204~209 (2003)
- Kansagara D, "Screening for hepatocellular carcinoma in chronic liver disease : a systematic review", Ann Intern Med, 161, pp.261~269 (2014)
- Lederle FA, "Screening for liver cancer : the rush to judgment", Ann Intern Med, 156, pp.387~389 (2012)
- Zhao C, "Poor adherence to hepatocellular carcinoma surveillance : a systematic review and meta-analysis of a complex issue", Liver Int, 38, pp.503~514 (2018)
- Kim Y, "Overview of the national cancer screening programme and the cancer screening status in Korea", Asian Pac J Cancer Prev, 12, pp.725~730 (2011)
- 송선옥, "Background and Data Configuration Process of a Nationwide Population-Based Study Using the Korean National Health Insurance System", Diabetes and Metabolism Journal, 38(5), pp.395~403 (2014), 대한당뇨병학회[DOI]
- Shin DW, "Korean national health insurance database", JAMA Intern Med, 176, pp.138~ (2016)
- Noh DK, "Factors associated with attending the national cancer screening program for liver cancer in Korea", Asian Pac J Cancer Prev, 13, pp.731~736 (2012)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- Dekker FW, "Survival analysis : time-dependent effects and time-varying risk factors", Kidney Int, 74, pp.994~997 (2008)
- Cucchetti A, "Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma", J Hepatol, 61, pp.333~341 (2014)
- Llovet JM, "Hepatocellular carcinoma", Nat Rev Dis Primers, 2, pp.16018~ (2016)
- Villanueva A, "Hepatocellular carcinoma", N Engl J Med, 380, pp.1450~1462 (2019)
- Kudo M, "Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan", Liver Cancer, 4, pp.39~50 (2015)
- Kudo M, "Japan’s successful model of nationwide hepatocellular carcinoma surveillance highlighting the urgent need for global surveillance", Liver Cancer, 1, pp.141~143 (2012)
- Wu CY, "Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma : a nationwide cohort study", Gut, 65, pp.693~701 (2016)
- Leykum LK, "Screening for hepatocellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival", Clin Gastroenterol Hepatol, 5, pp.508~512 (2007)
- Yang JD, "Factors that affect risk for hepatocellular carcinoma and effects of surveillance", Clin Gastroenterol Hepatol, 9, pp.617~623 (2011)
- Atiq O, "An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis", Hepatology, 65, pp.1196~1205 (2017)
- Ibrahim A. Hanouneh, "Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?", Clinical and Molecular Hepatology, 25(3), pp.264~269 (2019), 대한간학회
- 신윤희, "Disease-Specific Mortality and Prevalence Trends in Korea, 2002–2015", Journal of Korean Medical Science, 35(4), pp.1~12 (2020), 대한의학회[DOI]